Stereotaxis to highlight results from Epoch clinical study at HRS annual meeting

Stereotaxis, Inc. (NASDAQ:   STXS) will highlight clinical results from the first 1,250 cases and the latest innovations for the Epoch™ platform, its new generation comprehensive solution for the electrophysiology (EP) laboratory, at the 33rd Annual Heart Rhythm Society (HRS) Scientific Sessions, May 9-12, 2012. 

The formal HRS academic program features multiple invited presentations, podium presentations, and posters detailing Stereotaxis' clinical results in a wide variety of arrhythmias. A total of 11 invited podium presentations feature use of Stereotaxis magnetic navigation technology.   In addition, 13 submitted abstracts that feature or discuss Stereotaxis technology are included in this year's HRS program.  Highlights of these submitted abstracts include comparative data on VT ablation, multi-center VT data, lesion formation, pediatric outcome data, and the first large series of Vdrive™ system's clinical outcomes data.

Stereotaxis will be at booth number 1307, providing demonstrations of commercially available products and a technical suite for obtaining input on new product innovations from select physician customers.  In addition, the Company will feature at the booth a speaker series where customers will share their experiences with the Epoch™ and Odyssey™ product platforms.  In-booth speakers include:

  • Dr. Robert Schweikert from Akron General Medical Center on the Odyssey™ Solution (May 10 at 9:30 am ET);
  • Dr. Yaariv Khaykin from Southlake Regional Health Center on the Odyssey™ Solution (May 10 at 10:00 am ET); and
  • Dr. J. Peter Weiss from Intermountain Medical Center on the Epoch™ Solution (May 10 at 3:45 pm ET and May 11 at 10:00 am ET). 

Stereotaxis will unveil a broad number of product innovations for the Niobe® ES, Vdrive™ and Odyssey™ platforms scheduled to be shipped in 2012.  The innovations include advancements in linear line formation and testing, Vdrive™ offering and Odyssey™ remote collaboration. 

"Stereotaxis will launch exciting advancements at the upcoming HRS congress, which will further enhance the value we bring to the EP market," said Michael P. Kaminski, President and Chief Executive Officer of Stereotaxis.  The 2012 innovations for the Niobe® ES and Odyssey™ product platforms as well as the new Vdrive™ platform demonstrate our continued commitment to providing new solutions for the EP market."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
CRISPR-based therapy shown to be safe, effective for people with transthyretin amyloidosis